Stockreport

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting [Yahoo! Finance]

Xenon Pharmaceuticals Inc. - Common Shares  (XENE) 
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.xenon-pharma.com
PDF X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 10 [Read more]